Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of S086 tablets versus olmesartan in mild to moderate essential hypertension
ChiCTR2100051183Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of S086 in essential hypertension (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Change from baseline in mean seated systolic blood pressure. Started Oct 2021; status: recruiting.
02
Drugs
S086
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2100051183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051183.